Ravneesh Sachdev is Vice President, Business Development at Bioverativ based just outside Boston. Newly spun-off from Biogen in early 2017, Bioverativ’s mission is to transform the lives of people with rare blood disorders. Ravneesh evaluates and transacts on partnerships (including licensing deals, mergers and acquisitions) in order to inorganically grow Bioverativ’s business. Over the past 10+ years of his business development career, Ravneesh has contributed to, as well as, led the execution of more than 15 partnerships during his tenure at several other companies, namely Pfizer, Onyx Pharmaceuticals (now part of Amgen), UCB Pharma and Acorda Therapeutics. Ravneesh earned his BS in Molecular Neuroscience from Claremont McKenna College with honors, his MBS from KGI in 2006, and his MBA from Yale University School of Management. Ravneesh has organized a speaker series event in South San Francisco, served as the Admissions Chairman for KGI’s inaugural Alumni Board, donates towards the KGI Annual Fund, and mentors current students and alumni on career opportunities.